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Prokineticin 2 (Prok2) or prokineticin-receptor2 (Prok-R2) gene mutations are associated with Kallmann syndrome
(KS). We describe a new homozygous mutation of Prok-R2 gene in a man displaying KS with an apparent reversal of
hypogonadism. The proband, offspring of consanguineous parents, presented at age 19 years with absent puberty, no
sense of smell, low testosterone and gonadotrophin levels. Magnetic resonance imaging showed olfactory bulb absence.
The patient achieved virilization and spermatogenesis with gonadotrophin administration. Two years after disconti-
nuing hormonal therapy, he maintained moderate oligozoospermia and normal testosterone levels. Prok2 and Prok-
R2 gene sequence analyses were performed. The proband had a homozygous mutation in Prok-R2 exon 2 that har-
bours the c.T820>A base substitution, causing the introduction of an aspartic acid in place of valine at position 274
(Val274Asp). His mother had the same mutation in heterozygous state. This report describes a novel homozygous
mutation of Prok-R2 gene in a man with variant KS, underlying the role of Prok-R2 gene in the olfactory and repro-
ductive system development in humans. Present findings indicate that markedly delayed activation of gonadotrophin
secretion may occur in some KS cases with definite gene defects, and that oligozoospermia might result from a variant
form of reversible hypogonadotrophic hypogonadism.
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Kallmann syndrome (KS) is a congenital form of idiopathic
hypogonadotrophic hypogonadism (iHH) in which gonado-
trophin deficiency is associated with defective sense of smell
(anosmia or hyposmia) (Seminara et al., 2003). These altera-
tions are thought to be secondary to impaired migration of
GnRH-secreting and olfactory neurons from the olfactory
placode region to the hypothalamus (Schwanzel-Fukuda
et al., 1989; Gonzales-Martines et al., 2004; Cariboni and
Maggi, 2006). KS is a heterogeneous disease in terms of vari-
able reproductive phenotype and complex genetic transmission
(Quinton et al., 1999, 2001; Seminara et al., 2003). Several
monogenic defects have been described for KS, including
X-linked KAL-1 gene mutations (Franco et al., 1991;
Legouis et al., 1991) and autosomal-dominant fibroblast
growth factor receptor 1 (FGFR1) gene (or KAL2) mutations
(Dode´ et al., 2003; Pitteloud et al., 2006). Recently, the role
of two genes encoding prokineticin 2 (Prok2) and its receptor
(Prok-R2) in the neurogenesis of olfactory bulbs and GnRH
neuron migration has been suggested by evidence of KS pheno-
type in KO mice (Ng et al., 2005; Matsumoto et al., 2006; Pit-
teloud et al., 2007a, b). Moreover, mutations of either Prok2 or
Prok-R2 human orthologs have been described in some KS
patients (Dode´ et al., 2006; Pitteloud et al., 2007a, b; Leroy
et al., 2008). Variable degrees of olfactory and reproductive
dysfunctions have been reported in subjects across and within
families carrying the same mutation, suggesting incomplete
penetrance and an influence of modifier genes or environmental
factors (Quinton et al., 1999, 2001; Seminara et al., 2003;
Pitteloud et al., 2007a, b). Although impaired sexual
maturation with absent, partial or delayed puberty is the main
reproductive phenotype in KS, a variant form known as revers-
ible KS has been described in several cases, in which gonado-
trophins, testosterone and fertility recover spontaneously
(Quinton et al., 1999; Pitteloud et al., 2005; Ribeiro et al.,
2007; Raivio et al., 2007). Mutations of known genes respon-
sible of iHH [KAL1, FGFR1, GnRH receptor (GnRHR)]†These authors contributed equally to this work.
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have been described in some KS variant (Pitteloud et al., 2001,
2005; Lin et al., 2006; Raivio et al., 2007; Ribeiro et al., 2007).
In this report we describe a man with a variant KS carrying a
new homozygous mutation of Prok-R2 gene displaying an
apparent reversal of his reproductive condition following 5
year hormone replacement therapy. This study extends our
understanding about the role of Prok2–Prok-R2 gene pathways
in the regulation of olfactory and gonadal system development
and function in humans.
Case presentation
Written informed consent was obtained from the proband,
mother and normal individuals used as controls. The study
was performed under ethical approval of the Institutional
Review Board. The proband, a 19-year-old male presented to
the Endocrine Unit of Second University Hospital with
absent puberty. Physical examination revealed eunuchoidal
body proportions with a height of 169 cm, an arm span of
182 cm, an upper to lower segment ratio of 0.8, a weight of
57 kg and a BMI of 20 kg/m2. He had no beard, puberal
Tanner stage 1, a stretched phallus length of 3.5 cm, scrotal
testes of 3 ml bilaterally, absence of ginecomastia, synkinesis,
hearing loss, dental agenesis and midline defects. He had
anosmia, confirmed by modified formal smelling test (Doty
et al., 1984), and normal colour perception at Ishihara tests
(Kanehara Shuppan Co., Tokyo, Japan). Family history,
obtained by proband and his mother revealed parental consan-
guinity (Fig. 1). He was an only child of first-cousin parents.
The 39-year-old mother had had a delayed menarche at 15
year, followed by regular menstrual cycles, and had always
had a normal sense of smell. The father was not available for
clinical and genetic examination.
Clinical study
Clinical, hormonal and seminal data at first observation and
during follow-up are summarized in Table I. At diagnosis
FSH, LH, testosterone and inhibin B levels were low. After a
GnRH stimulation test, FSH and LH peaked to 2.3 and
1.2 mIU/ml, respectively. Baseline prolactin, thyroid and
adrenal hormone levels were normal. The growth
hormone-insulin-like growth factor 1 axis was also normal,
basally and after stimulation testing. Magnetic resonance
imaging showed absence of olfactory bulbs and a normal hypo-
thalamic pituitary region. Diagnosis of KS was made and repla-
cement therapy with hCG alone (Gonasi HP, AMSA, Italy,
1000–2000 IU i.m. twice a week) was started. After 1 year
of therapy, the patient achieved puberal Tanner stage 3 and a
testis volume of 5 ml. Semen analysis showed azoospermia.
Recombinant FSH (Gonal F, Serono, Swizereland 75 IU s.c.
twice a week) was added to hCG. After 1 year of combined
therapy, serum testosterone level was 21 nmol/l, and seminal
analysis, performed according World Health Organization
guidelines (1992), showed moderate oligozoospermia. Then
the patient continued with hCG alone (2000 IU two times a
week). A re-evaluation after 6 months showed a normal testos-
terone value and oligozoospermia. On patient demand testos-
terone replacement therapy (testosterone enanthate, TE,
250 mg i.m. every 3 weeks) was prescribed instead of
gonadotrophins, to maintain virilization and sexual activity.
After 3 years of TE therapy, the patient presented increased
testis size, supranormal testosterone levels and persistent sper-
matogenesis. He referred spontaneously interrupted pregnancy
in his partner. TE administration was discontinued and
re-examination recommended. Six months after discontinuing
therapy he had preserved sexual activity, normal testosterone,
FSH and LH levels, and mild oligozoospermia. The patient
was discharged without therapy and re-evaluated after 2
years. At this time, gonadotrophin levels were normal, testos-
terone was in the low level of adult range (11.45 nmol/l) and
seminal analysis revealed persistence of moderate oligozoos-
permia (Table I).
Genetic study
Genomic DNA was obtained from peripheral blood samples by
using Wizard Genomic DNA Purification Kit (Promega).
Primers used for amplification and sequencing of Prok2
(NCBI Gene ID: 60675) and Prok-R2 (NCBI Gene ID:
128674) coding exons were designed on the basis of reported
sequences (Dode´ et al., 2006). PCRs were performed using
Figure 1: Family pedigree.
The arrow indicates the proband (A). DNA sequence electrophoreto-
grams showing the prokineticin-receptor2 (Prok-R2) homozygous
c.T830.A base substitutation (p.Val274Arg) in the proband with
Kallmann Syndrome (B) and the heterozygous mutation in the
mother (C). Interspecies comparison of the amino acid sequences of
Prok-R2 around the mutated residue (D) demonstrating high conserva-
tion in primates, dog and rodents.
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15 pmol of each primer and 20 ng of genomic DNA in a final
volume of 25 ml. Thirty-five cycles of PCR were carried out
to amplify all exons, with 5 min of initial denaturation at
948C followed by 30 s denaturation at 948C, 30 s annealing
at 558C, 30 s extension at 728C, and a final 7 min extension
at 728C to ensure that all amplicons were completely extended.
The primers and programmes used for KAL1, FGFR1 and
GnRHR coding exon analysis have been reported elsewhere
(Hardelin et al., 1993; Sato et al., 2004; Antelli et al., 2006).
Results
In the proband, sequence analysis did not identify any mutation
in the exons of Prok2 gene. In contrast, analysis of Prok-R2
showed a homozygous mutation in the second exon of the
gene that harbours the c.T820.A base substitution (Fig. 1B).
This mutation was absent in our 100 control chromosomes.
This mutation causes the introduction of an aspartic acid at the
place of a valine in position 274 (Val274Asp). The proband
mother sequence analysis showed the same heterozygous
mutation (Fig. 1C). This amino acid is localized in a highly con-
served domain of the protein (Fig. 1D), likely corresponding to
the third intracellular loop. This domain is probably involved
in transduction-signal pathway. We submitted the wild type
and the substituted amino acid sequence to bioinformatic
tools (SwissModel and EsyPred3D) to create a computational
three-dimensional model. The overlap between wild-type and
mutated sequence model obtained with SwissModel shows a
mismatch in the mutated region suggesting that this amino
acid substitution probably modified protein three-dimensional
structure (data not shown). The same result was obtained
using EsyPred3D tool. Sequence analysis excluded KAL1,
FGFR1 and GnRHR gene mutations in the proband.
Discussion
This report describes reversal of hypogonadotrophic hypogo-
nadism in a patient with KS carrying a novel homozygous
mutation in Prok-R2 gene. The patient harbours a T/A base
substitution at codon 274 of Prok-R2 gene, leading to a
Val274Asp mutation in the receptor protein, associated with
hypogonadotrophic hypogonadism and anosmia due to olfac-
tory system anomalies. This base substitution does not rep-
resent a common polymorphic variant in the population of
our country, as it was absent in a series of 100 alleles from
50 ethnically matched controls (10 women and 40 men). The
proband inherited the trait from consanguineous parents. His
mother, who had had a delayed menarche but a normal sense
of smell, showed the same heterozygous mutation in Prok-R2
gene. His father was unavailable for clinical and genetic
Table I. Clinical, endocrine and seminal data in a man displaying Kallmann syndrome.
Observation 1 (diagnosis) 2 3 4 5 6 7
Age (years) 19 20 21 21.5 24.5 25 27
Therapy None hCG hCG þ rFSH hCG TE None None
Mean testicular volume (ml) 3 5 11 11 18 18 20 Normal values
FSH (mIU/ml) 0.1 – – – – 5.1 4.9 1.5–9.0
LH (mIU/ml) 0.5 – – – – 7 5.8 2.0–10
Testosterone (nmol/l) 0.52 9.69 21.11 25.6 32.87 15.92 11.42 11.07–31.1
Inhibin B (pg/ml) 70 125 144 156 – – – 50–250
TSC (millions) – 0 28 24 37.5 27 18 .40a
SC (mil/ml) – 0 14 12 16 18 9 .20a
Progressive motility, % – – 40 10 25 20 30 .50a
aWorld Health Organization manual 1992. TSC, total sperm count; SC, sperm concentration; TE, testosterone enanthate.
Table II. Cases of reversible iHH associated with gene mutations.
References At diagnosis At reversal Gene
Age,
Years
Mean
TS, ml
FSH,
mIU/
ml
LH,
mIU/
ml
Testosterone,
nmol/l
Age,
Years
Mean
TS, ml
FSH,
mIU/
ml
LH,
mIU/
ml
Testosterone,
nmol/l
SC,
mil/
ml
TR,
Years
Pitteloud et al.
(2005), Raivio
et al. (2007)
18 6 1.6 1.6 0.35 24 9.5 11.7 11.5 11.76 4 5 FGFR1
Raivio et al. (2007) 20 11 2.7 6.8 2.94 27 14 6.3 14.6 53.51 0.1 1.9 FGFR1
Ribeiro et al.
(2007)
22 3 7.27 42 16 16.61 KAL1
Pitteloud et al.
(2001)
30 17 2.4 3.7 3.1 26.7 20 3.9 7.1 12.5 91.4 0.5 GnRHR
Lin et al. (2006) 15.9 32 8.5 5.9 12.5 18 GnRHR
Present case 19 3 0.1 0.5 0.52 27 20 4.9 5.8 11.42 9 5.5 Prok-R2
TS, testicular size; TR, time to reversal; FGFR, fibroblast growth factor receptor 1; GnRHR, gnRH receptor; Prok-R2, prokineticin-receptor2.
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studies, but the state of consanguinity suggests a possible het-
erozygous condition too. Studies on mutant mice lacking Prok2
or Prok-R2 genes indicated that Prok2/Prok-R2 signalling is
critical for neurogenesis of olfactory bulbs and GnRH neuron
migration (Ng et al., 2005; Matsumoto et al., 2006; Pitteloud
et al., 2007a, b). The phenotype in our patient resembles that
of mice with homozygous Prok-R2 mutations, which had
abnormal development of the olfactory bulb and reproductive
system atrophy (Ng et al., 2005). Dode´ et al. (2006) first
described mutations in Prok-R2 gene in 10% of a cohort of
192 KS male and female patients. Mutations in Prok2 gene,
coding for a ligand of Prok-R2, were also described (Dode´
et al., 2006; Pitteloud et al., 2007a, b; Leroy et al., 2008).
Such findings and the present report indicate that Prok2 and
Prok-R2 genes, as well as KAL1 and FGFR1, may be involved
in olfactory bulb development and GnRH neuron migration in
humans too. Both Prok2 and Prok-R2 mutations do not appear
to be associated with clinical anomalies (bimanual synkinesis,
renal agenesis and midline defects) reported in other genetic
forms of the disease. The homozygous mutation in our
proband is located in the second exon, in a highly conserved
region of Prok-R2 gene that probably encodes the third intra-
cellular loop, suggesting a critical role of this residue in recep-
tor function. It is noteworthy that 8 out 10 mutations described
by Dode´ et al. (2006) have been found in exon 2 of the gene.
However, the exact biological role of the mutation is still
unclear, in absence of functional studies. The substitution of
a neutral amino acid, such as valine, with the polar aminoacid
asparagine can induce modifications in the three-dimensional
assembling of the Prok-R2 protein, causing changes in
protein–protein interactions, as suggested by computational
analysis. This structural change can lead to abnormal receptor
dimerization or impaired intracellular signalling.
Prok-R2 mutations were found in the homozygous state only in
two cases, whereas in the others they appear in heterozygous or in
compound heterozygous state (Dode´ et al., 2006). Moreover,
these patients presented variable degree of olfactory and repro-
ductive dysfunction (anosmia, hyposmia, delayed puberty or
hypogonadotrophic hypogonadism). In our family, the homozy-
gous proband had a more severe phenotype than his heterozygous
mother who presented only with delayed menarche. The presence
of complete phenotype in Prok-R2 heterozygous patients might
be explained by the co-existence of additional inherited altera-
tions in other genes involved in reproductive and olfactory
system development and function (Dode´ et al., 2006; Pitteloud
et al., 2007a, b; Leroy et al., 2008). In fact, heterozygous
FGFR1 mutations have been found associated with additional
mutations in nasal embryonic LHRH factor (NELF) and
GnRHR genes in two families, indicating that, at least in some
pedigree, KS may have a digenic inheritance (Pitteloud et al.,
2007a, b). Moreover, Dode´ et al. (2006) reported a subject
with KS who exhibited combined mutation of PKR2 and
KAL1, indicating that in some instances the syndrome may be
an oligogenic trait. However, mutations in Prok2, KAL1,
FGFR1 and GnRHR genes were not detected in our family.
The patient achieved complete virilization and fertility under
gonadotrophin substitution therapy. Reversal of his hypogo-
nadism was suggested by maintenance of spermatogenesis
and fertility under long-term TE administration. Persistent
normalization of pituitary–gonadal hormones after a further
2 years without TE replacement therapy indicates a reversal
of hypogonadotrophic hypogonadism state. This is in accord-
ance with recently established criteria (Raivio et al., 2007).
KS reversible phenotype is a variant that may be found more
frequently than suspected. In fact, Raivio et al. (2007) found
hypogonadotrophic hypogonadism reversal in 10% of cases.
Definite gene alterations have been reported in three out of
13 subjects examined by Raivio et al. (2007) and in single
cases by others (Pitteloud et al., 2001, 2005; Lin et al., 2006;
Ribeiro et al., 2007) (Table II). Reversible KS has been
reported in patients carrying FGFR1 and KAL1 gene mutations
(Pitteloud et al., 2005; Ribeiro et al., 2007; Raivio et al., 2007).
Moreover, alterations in GnRHR gene have been found in
two patients with mild forms of iHH: one with fertile eunuch
syndrome and another two with a history of delayed puberty
(Pitteloud et al., 2001; Lin et al., 2006). In the present study,
we have demonstrated for the first time that reversible KS
may be associated with a Prok-R2 mutation. The pathophysiol-
ogy of hypogonadotrophic hypogonadism reversal and the
interplay between different genes involved in the ontogeny
and growth of GnRH system still remain unclear. We can
hypothize that some gene mutations may be associated with a
partial migration defect of GnRH neurons, resulting in variable
degrees of impaired gonadotrophin secretion, but supportive
evidence is still lacking. GnRH neuron migration and growth
may be stimulated after the embryonic period by exogenous
or endogenous sex steroids, contributing to the recovery of
pituitary–gonadal function. Present and previous findings
(Pitteloud et al., 2005; Ribeiro et al., 2007; Raivio et al.,
2007) indicate that hypogonadotrophic hypogonadism cannot
be considered an irreversible state in all the subjects harbouring
genetic mutations in known genes involved in the control
of gonadotrophin secretion pathway. Thus, the markedly
delayed activation of gonadotrophin secretion in a subgroup
of KS patients might be one extreme on a phenotypic spectrum
of disorders characterized by altered regulation of the GnRH
pulse generator, including constitutional delay of puberty
and functional hypogonadism (Bhasin, 2007). From a clinical
perspective, a periodic re-examination is advisable after
discontinuing therapy to evaluate a possible reversal of
hypogonadotrophic hypogonadism. Furthermore, these
subjects with variant KS may provide the evidence that oligo-
zoospermia in a subset of infertile men can result from partial
and reversible hypogonadotrophic hypogonadism. Thus, the
identification of such variant iHH may offer new therapeutic
approaches to male infertility.
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